Literature DB >> 30569330

Predicting underestimation of ductal carcinoma in situ: a comparison between radiomics and conventional approaches.

Jiao Li1, Yan Song2, Shuoyu Xu1, Jinhua Wang3, Huabin Huang1, Weimei Ma1, Xinhua Jiang1, Yaopan Wu1, Hongming Cai2, Li Li4.   

Abstract

PURPOSE: We aimed to investigate the feasibility of predicting invasion carcinoma from ductal carcinoma in situ (DCIS) lesions diagnosed by preoperative core needle biopsy using radiomics signatures, clinical imaging characteristics, and breast imaging reporting and data system (BI-RADS) descriptors on mammography.
METHODS: Retrospectively, we enrolled 362 DCIS patients diagnosed by core needle biopsy, 110 (30.4%) of which had invasive carcinoma confirmed by operation and pathology. We analyzed the images identified suspicious calcification from 250 subjects (161 pure DCIS and 89 DCIS with invasion). A total of 569 calcification radiomics signatures were extracted from microcalcification for each patient. We included a group of routine clinical imaging characteristics and BI-RADS descriptors for comparison purpose. Five feature selection and seven classification methods were evaluated in terms of their prediction performance. We compared the area under the receiver operating characteristic curve (AUC) averaged from tenfold cross-validation of different feature sets to identify the best combination of feature selection and classification methods.
RESULTS: Optimal feature selection and classification methods were identified after evaluating various combinations of feature sets. The best performance was achieved using both radiomics and clinical imaging characteristics (AUC = 0.72) performing better than BI-RADS descriptors or radiomics, but was no significant difference with clinical imaging characteristics (AUC = 0.66). The most significant features found were morphology signatures, first-order statistics, asymmetry/mass prevalence, and nuclear grade.
CONCLUSIONS: We found that the prediction model established using microcalcifications radiomics signatures and clinical imaging characteristics has the potential to identify an understaging of invasive breast cancer.

Entities:  

Keywords:  Ductal carcinoma in situ; Machine learning; Mammography; Microcalcification; Radiomics

Mesh:

Year:  2018        PMID: 30569330     DOI: 10.1007/s11548-018-1900-x

Source DB:  PubMed          Journal:  Int J Comput Assist Radiol Surg        ISSN: 1861-6410            Impact factor:   2.924


  5 in total

Review 1.  Artificial Intelligence for Mammography and Digital Breast Tomosynthesis: Current Concepts and Future Perspectives.

Authors:  Krzysztof J Geras; Ritse M Mann; Linda Moy
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

2.  Clinicopathologic breast cancer characteristics: predictions using global textural features of the ipsilateral breast mammogram.

Authors:  Ibrahem H Kanbayti; William I D Rae; Mark F McEntee; Ziba Gandomkar; Ernest U Ekpo
Journal:  Radiol Phys Technol       Date:  2021-06-02

3.  Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer.

Authors:  Ko Woon Park; Seon Woo Kim; Heewon Han; Minsu Park; Boo-Kyung Han; Eun Young Ko; Ji Soo Choi; Eun Yoon Cho; Soo Youn Cho; Eun Sook Ko
Journal:  NPJ Breast Cancer       Date:  2022-01-14

4.  Ipsilateral Recurrence of DCIS in Relation to Radiomics Features on Contrast Enhanced Breast MRI.

Authors:  Ga Eun Park; Sung Hun Kim; Eun Byul Lee; Yoonho Nam; Wonmo Sung
Journal:  Tomography       Date:  2022-03-01

5.  A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast.

Authors:  Luca Nicosia; Anna Carla Bozzini; Silvia Penco; Chiara Trentin; Maria Pizzamiglio; Matteo Lazzeroni; Germana Lissidini; Paolo Veronesi; Gabriel Farante; Samuele Frassoni; Vincenzo Bagnardi; Cristiana Fodor; Nicola Fusco; Elham Sajjadi; Enrico Cassano; Filippo Pesapane
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.